D-0553-2023 Class II Ongoing
FDA drug recall D-0553-2023 was initiated by Northwind Pharmaceuticals LLC on Mar 16, 2023 and is designated Class II. Reason for recall: CGMP Deviations The recall status is ongoing. Affected quantity: a)164 bottles; b) 198 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- May 3, 2023
- Initiation Date
- Mar 16, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a)164 bottles; b) 198 bottles
Product description
Tadalafil Tablets, USP 20 mg, packaged in a) 6-count bottles (NDC 51655-473-87), and b) 15-count bottles (NDC 51655-473-54), Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203.
Reason for recall
CGMP Deviations
Distribution pattern
Nationwide with the United States
Code information
a) Lot #: F113892002, Exp. Date 08/31/2023; F113892201, Exp. Date 11/30/2023 b) Lot #: F113892001, Exp. Date 08/31/2023; F113892202, Exp. Date 11/30/2023; F113892203, Exp. Date 12/31/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0553-2023
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026